Rationale: Lung dysbiosis promotes airway inflammation and decreased local immunity, potentially playing a role in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Objectives: We sought to determine the relationship between sputum microbiome at the time of AECOPD hospitalization and 1-year mortality in a COPD cohort. Methods: We used sputum samples from 102 patients hospitalized because of AECOPD. All subjects were followed for 1 year after discharge. The microbiome profile was assessed through sequencing of 16S rRNA gene. Microbiome analyses were performed according to 1-year mortality status. To investigate the effect of α-diversity measures and taxon features on time to death, we applied Cox proportional hazards regression models and obtained hazard ratios (HRs) associated with these variables. Measurements and Main Results: We observed significantly lower values of α-diversity (richness, Shannon index, evenness, and Faith's Phylogenetic Diversity) among nonsurvivors (n = 19, 18.6%) than survivors (n = 83, 81.4%). β-Diversity analysis also demonstrated significant differences between both groups (adjusted permutational multivariate ANOVA, P = 0.010). The survivors had a higher relative abundance of Veillonella; in contrast, nonsurvivors had a higher abundance of Staphylococcus. The adjusted HRs for 1-year mortality increased significantly with decreasing α-diversity. We also observed lower survival among patients in whom sputum samples were negative for Veillonella (HR, 13.5; 95% confidence interval, 4.2-43.9; P < 0.001) or positive for Staphylococcus (HR, 7.3; 95% confidence interval, 1.6-33.2; P = 0.01). Conclusions: The microbiome profile of sputum in AECOPD is associated with 1-year mortality and may be used to identify subjects with a poor prognosis at the time of hospitalization.
Rationale: Lung dysbiosis promotes airway inflammation and decreased local immunity, potentially playing a role in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Objectives: We sought to determine the relationship between sputum microbiome at the time of AECOPD hospitalization and 1-year mortality in a COPD cohort. Methods: We used sputum samples from 102 patients hospitalized because of AECOPD. All subjects were followed for 1 year after discharge. The microbiome profile was assessed through sequencing of 16S rRNA gene. Microbiome analyses were performed according to 1-year mortality status. To investigate the effect of α-diversity measures and taxon features on time to death, we applied Cox proportional hazards regression models and obtained hazard ratios (HRs) associated with these variables. Measurements and Main Results: We observed significantly lower values of α-diversity (richness, Shannon index, evenness, and Faith's Phylogenetic Diversity) among nonsurvivors (n = 19, 18.6%) than survivors (n = 83, 81.4%). β-Diversity analysis also demonstrated significant differences between both groups (adjusted permutational multivariate ANOVA, P = 0.010). The survivors had a higher relative abundance of Veillonella; in contrast, nonsurvivors had a higher abundance of Staphylococcus. The adjusted HRs for 1-year mortality increased significantly with decreasing α-diversity. We also observed lower survival among patients in whom sputum samples were negative for Veillonella (HR, 13.5; 95% confidence interval, 4.2-43.9; P < 0.001) or positive for Staphylococcus (HR, 7.3; 95% confidence interval, 1.6-33.2; P = 0.01). Conclusions: The microbiome profile of sputum in AECOPD is associated with 1-year mortality and may be used to identify subjects with a poor prognosis at the time of hospitalization.
Authors: Sharon M Carney; Jose C Clemente; Michael J Cox; Robert P Dickson; Yvonne J Huang; Georgios D Kitsios; Kirsten M Kloepfer; Janice M Leung; Tricia D LeVan; Philip L Molyneaux; Bethany B Moore; David N O'Dwyer; Leopoldo N Segal; Stavros Garantziotis Journal: Am J Respir Cell Mol Biol Date: 2020-03 Impact factor: 6.914
Authors: Robert P Dickson; Marcus J Schultz; Tom van der Poll; Laura R Schouten; Nicole R Falkowski; Jenna E Luth; Michael W Sjoding; Christopher A Brown; Rishi Chanderraj; Gary B Huffnagle; Lieuwe D J Bos Journal: Am J Respir Crit Care Med Date: 2020-03-01 Impact factor: 21.405
Authors: Michael P Combs; David S Wheeler; Jenna E Luth; Nicole R Falkowski; Natalie M Walker; John R Erb-Downward; Vibha N Lama; Robert P Dickson Journal: Lancet Respir Med Date: 2021-01-15 Impact factor: 30.700
Authors: Jennifer M Baker; Kevin J Hinkle; Roderick A McDonald; Christopher A Brown; Nicole R Falkowski; Gary B Huffnagle; Robert P Dickson Journal: Microbiome Date: 2021-05-05 Impact factor: 14.650
Authors: Rami Sommerstein; Tobias M Merz; Sabine Berger; Julia G Kraemer; Jonas Marschall; Markus Hilty Journal: Antimicrob Resist Infect Control Date: 2019-05-22 Impact factor: 4.887
Authors: Martin I MacDonald; Christian R Osadnik; Lauren Bulfin; Elizabeth Leahy; Paul Leong; Eskandarain Shafuddin; Kais Hamza; Paul T King; Philip G Bardin Journal: ERJ Open Res Date: 2021-07-12